Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.

doi:10.1126/scitranslmed.aah6144

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.

Science translational medicine - 14 Jun 2017

Plenker Dennis, Riedel Maximilian, Brägelmann Johannes, Dammert Marcel A, Chauhan Rakhee, Knowles Phillip P, Lorenz Carina, Keul Marina, Bührmann Mike, Pagel Oliver, Tischler Verena, Scheel Andreas H, Schütte Daniel, Song Yanrui, Stark Justina, Mrugalla Florian, Alber Yannic, Richters André, Engel Julian, Leenders Frauke, Heuckmann Johannes M, Wolf Jürgen, Diebold Joachim, Pall Georg, Peifer Martin, Aerts Maarten, Gevaert Kris, Zahedi René P, Buettner Reinhard, Shokat Kevan M, McDonald Neil Q, Kast Stefan M, Gautschi Oliver, Thomas Roman K, Sos Martin L

Abstract excerpt

Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. We provide further evidence that current anti-RET drugs may not be potent enough to induce durable responses in such tumors. We report that potent inhibitors, such as AD80 or ponatinib, that stably bind in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytoskeletal Proteins

Share to Gene Rearrangement

Share to Heterocyclic Compounds, 4 or More Rings

Share to Imidazoles

Share to NIH 3T3 Cells

Share to Proto-Oncogene Proteins c-ret

Share to Pyridazines

Source

Open in PubMed Open full text

Identifiers

PMID: 28615362
DOI: 10.1126/scitranslmed.aah6144
PMCID: PMC5805089

Genes

RET
CCDC6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.PMID 28615362Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

RET fusions observed in lung and colorectal cancers are sensitive to ponatinibSemantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read ↗

Therapeutic strategies in RET gene rearranged non-small cell lung cancerSemantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.